Antibiotice Valuation

Q: What is the Fair Price of ATB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ATB (RON3.31) is trading below our estimate of [[fair value]] (RON3.36)

Is ATB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ATB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ATB (RON3.31) is trading below our estimate of fair value (RON3.36)

Significantly Below Fair Value: ATB is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ATB?

Key metric: As ATB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ATB. This is calculated by dividing ATB's market cap by their current earnings.
What is ATB's PE Ratio?
PE Ratio	23.8x
Earnings	RON 93.28m
Market Cap	RON 2.21b

ATB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.5x
Enterprise Value/EBITDA	16.4x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does ATB's PE Ratio compare to its peers?

The above table shows the PE ratio for ATB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	18.2x
SCD Zentiva	11.6x	n/a	RON 3.2b
BIO Biofarm	10.6x	n/a	RON 739.0m
SINT S.C. Sintofarm	30.1x	n/a	RON 20.8m
4114 Synmosa Biopharma	20.4x	n/a	NT$14.6b
ATB Antibiotice	23.8x	n/a	RON 2.2b

Price-To-Earnings vs Peers: ATB is expensive based on its Price-To-Earnings Ratio (23.8x) compared to the peer average (18.2x).

Price to Earnings Ratio vs Industry

How does ATB's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: ATB is expensive based on its Price-To-Earnings Ratio (23.8x) compared to the European Pharmaceuticals industry average (21.1x).

Price to Earnings Ratio vs Fair Ratio

What is ATB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ATB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	23.8x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ATB's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.